Swipe om te navigeren naar een ander artikel
To understand how improvements in the symptoms of overactive bladder (OAB) seen with the β3-adrenoceptor agonist mirabegron 50 mg, correlate with patient experience as measured by validated and standard patient-reported outcomes (PROs), and to identify whether there is overall directional consistency in the responsiveness of PROs to treatment effect.
In a post hoc analysis of pooled data from three randomized, double-blind, placebo-controlled, 12-week Phase III trials of mirabegron 50 mg once daily, responder rates for incontinence frequency (≥50 % reduction in incontinence episodes/24 h from baseline to final visit), micturition frequency (≤8 micturitions/24 h at final visit), and PROs [minimally important differences in patient perception of bladder condition (PPBC) and subsets of the overactive bladder questionnaire (OAB-q) measuring total health-related quality of life (HRQoL), and symptom bother] were evaluated individually and in combination.
Mirabegron 50 mg demonstrated greater improvement from baseline to final visit than placebo for each of the responder analyses, whether for individual objective and subjective outcomes or combinations thereof. These improvements versus placebo were statistically significant for all double and triple responder analyses and for all single responder analyses except PPBC. PRO measurements showed directional consistency and significant correlations, and there were also significant correlations between objective and subjective measures of efficacy.
The improvements in objective measures seen with mirabegron 50 mg translate into a meaningful clinical benefit as evident by the directional consistency seen in HRQoL measures of benefit.
Haylen, B. T., de Ridder, D., Freeman, R. M., et al. (2010). An International Urogynecology Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourology and Urodynamics, 29, 4–20. PubMed
Irwin, D. E., Milsom, I., Hunskaar, S., et al. (2006). Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. European Urology, 50, 1306–1315.
Milsom, I., & Irwin, D. E. (2007). A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: Results from the EPIC study. European Urology Supplements, 6, 4–9.
Stewart, W. F., Van Rooyen, J. B., Cundiff, G. W., et al. (2003). Prevalence and burden of overactive bladder in the United States. World Journal of Urology, 20, 327–336. PubMed
Coyne, K. S., Sexton, C. C., Irwin, D. E., Kopp, Z. S., Kelleher, C. J., & Milsom, I. (2008). The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU International, 101(11), 1388–1395. PubMedCrossRef
Coyne, K. S., Kvasz, M., Ireland, A. M., Milsom, I., Kopp, Z. S., & Chapple, C. R. (2012). Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. European Urology, 61(1), 88–95. PubMedCrossRef
Sexton, C. C., Coyne, K. S., Thompson, C., Bavendam, T., Chen, C. I., & Markland, A. (2011). Prevalence and effect on health-related quality of life of overactive bladder in older Americans: Results from the epidemiology of lower urinary tract symptoms study. Journal of the American Geriatric Society, 59(8), 1465–1470.
Shah, S., & Nitti, V. W. (2009). Defining efficacy in the treatment of overactive bladder syndrome. Review in Urology, 11(4), 196–202.
Khullar, V. (2012). Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: What should we measure? International Urogynecology, 23, 179–192. CrossRef
Mattiasson, A., Djurhuus, J. C., Fonda, D., Lose, G., Nordling, J., & Stöhrer, M. (1998). Standardization of outcome studies in patients with lower urinary tract dysfunction: A report on general principles from the Standardisation Committee of the International Continence Society. Neurourology and Urodynamics, 17(3), 249–253. PubMedCrossRef
Dmochowski, R. R., Sand, P. K., Zinner, N. R., Gittelman, M. C., Davila, G. W., & Sanders, S. W. (2003). Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology, 62(2), 237–242. PubMedCrossRef
Shaya, F. T., Blume, S., Gu, A., Zyczynski, T., & Jumadilova, Z. (2005). Persistence with overactive bladder pharmacotherapy in a Medicaid population. American Journal of Managed Care, 11(4 Suppl), S121–S129. PubMed
Varadharajan, S., Jumadilova, Z., Girase, P., & Ollendorf, D. A. (2005). Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. American Journal of Managed Care, 11(4 Suppl), S140–S149. PubMed
D’Souza, A. O., Smith, M. J., Miller, L. A., Doyle, J., & Ariely, R. (2008). Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. Journal of Managed Care Pharmacy, 14(3), 291–301. PubMed
Zinner, N., Kobashi, K. C., Ebinger, U., Viegas, A., Egermark, M., Quebe-Fehling, E., et al. (2008). Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. International Journal of Clinical Practice, 62(11), 1664–1674. PubMedCentralPubMedCrossRef
Herschorn, S., Barkin, J., Castro-Diaz, D., Frankel, J. M., Espuna-Pons, M., Gousse, A. E., et al. (2013). A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to assess the efficacy and safety of the beta-3 agonist mirabegron in patients with symptoms of overactive bladder. Urology, 82(2), 313–320.
Nitti, V., Herschorn, S., Khullar, V., Cambronero, J., Angulo, J., Blauwet, M. B., et al. (2013). Efficacy of mirabegron in patients with overactive bladder: A pre-specified pooled analysis of three randomised, double-blind, placebo-controlled, phase III studies. International Journal of Clinical Practice, 67(7), 619–632. PubMedCentralPubMedCrossRef
Matza, L. S., Thompson, C. L., Krasnow, J., Brewster-Jordan, J., Zyczynski, T., & Coyne, K. S. (2005). Test–retest reliability of four questionnaires for patients with overactive bladder: The overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourology and Urodynamics, 24(3), 215–225. PubMedCrossRef
Dyer, K. Y., Xu, Y., Brubaker, L., Nygaard, I., Markland, A., Rahn, D., et al. (2011). Urinary incontinence treatment network (UITN). Minimum important difference for validated instruments in women with urge incontinence. Neurourology and Urodynamics, 30(7), 1319–1324. PubMed
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.
Coyne, K. S., Elinoff, V., Gordon, D. A., Deng, D. Y., Brodsky, M., Glasser, D. B., et al. (2008). Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. International Journal of Clinical Practice, 62(6), 925–931. PubMedCrossRef
Stewart, K., McGhan, W. F., Offerdahl, T., & Corey, R. (2002). Overactive bladder patients and role of the pharmacist. Journal of the American Pharmacists Association, 42(3), 469–476. CrossRef
Kelleher, C. J., Reese, P. R., Pleil, A. M., & Okano, G. J. (2002). Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. American Journal of Managed Care, 8(19 Suppl), S608–S615. PubMed
Kelleher, C. J., Dmochowski, R. R., Berriman, S., Kopp, Z. S., & Carlsson, M. (2012). Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: Pooled analysis of two open-label extension studies. BJU International, 110(3), 392–400. PubMedCrossRef
Van Kerrebroeck, P. E., Kelleher, C. J., Coyne, K. S., Kopp, Z., Brodsky, M., & Wang, J. T. (2009). Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health and Quality of Life Outcomes, 7, 131.
- The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
C. R. Chapple
M. B. Blauwet
- Springer International Publishing